Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2010 October;51(5) > The Journal of Cardiovascular Surgery 2010 October;51(5):747-54

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS  RECENT ADVANCES IN RENAL ARTERY STENTING 

The Journal of Cardiovascular Surgery 2010 October;51(5):747-54

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Efficacy of embolic protection devices in renal artery stenting

Campbell J. E. 1, Stone P. A. 1, Bates M. C. 1, 2

1 Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine, Charleston Division, Charleston, WV, USA 2 Vascular Center of Excellence, Charleston Area Medical Center, Charleston, WV, USA


PDF


The efficacy of embolic protection devices (EPDs) have been studied extensively in coronary saphenous vein grafts and extra cranial cerebrovascular disease. Recent ex-vivo and in-vivo renal artery stenting studies suggest atheroembolism is not unique to the coronary and cerebrovascular domain and it seems intuitive, renal EPDs may be beneficial. In an attempt to better understand the current objective evidence regarding renal protection efficacy we systematically reviewed the contemporary literature and summarize the findings herein. There is increasing observational data suggesting the use of embolic protection devices decrease the risk of continued decline in renal function after renal artery stenting. There is also prospective randomized data to suggest that the use of adjuvant IIb/IIIa glycoprotein inhibitor and embolic protection has synergistic benefit, but this is a very small series. However, there are currently no well controlled prospective trials to conclude the added risk and expense of renal protection is countered by proven clinical benefit. Based on the literature compiled in this manuscript we do believe EPDs should be considered in some high-risk patients.

top of page